REGN

NASD Regeneron Pharmaceuticals, Inc.

Nov 10, 2026 · 6:47 PM ET LAST TRADE Market Closed

$917.00 ↑ +0.94 (+0.10%) Trading Up from the previous close of $916.06, $2.72 below the day’s high of $919.72

YTD change: +18.80%
vs 20-day SMA: +8.43%
vs 200-day SMA: +23.39%

Price ranges

Previous day

$901.07 $933.36

open $922.35 close $919.96

-$2.39 (-0.26%)

Today

$905.38 $919.72

open $915.34 now $917.00

+$1.66 (+0.18%)

Past week

$887.04 $991.73

from $961.26 now $917.00

-$44.26 (-4.60%)

Past month

$743.57 $991.73

from $762.81 now $917.00

+$154.19 (+20.21%)

This year

$591.52 $991.73

from $771.87 now $917.00

+$145.13 (+18.80%)

Price & Performance

+207.19 (+29.07%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good

The stock is 24.3% away from all-time highs of $1,211.20
REGN is up 19% since the beginning of the year
REGN is up 40% over the past 12 months
REGN is up 20% over the past 1 month

REGN reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +40.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes

EPS $12.89

Earnings momentum -33.3% Quarterly EPS growth

Quarterly change -33.3%

Valuation

P/E ratio 19.96

Enterprise value $59.2B

Beta 0.16

Balance sheet & scale

Income$4.5M

Revenue$14.2B

Cash$7.5B

Debt$2.7M

Income / Debt 1.65×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $95.5B

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Competitor comparison

Ticker	Company	Price	Change
IQV	IQVIA Holdings Inc	$278.84	+2.58%
CRL	Charles River Laboratories International, Inc.	$353.34	+4.69%
ICLR	ICON Plc	$207.59	+1.39%
IT	Gartner, Inc.	$191.02	+0.48%
TGTX	TG Therapeutics, Inc.	$63.38	+5.94%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.